ArticleDigestion2026
<italic>Bifidobacterium bifidum</italic> G9-1 and Quality of Life in Chronic Constipation: A Multicenter, Double-Blind, Randomized Controlled Trial.
Article in Digestion, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPatients with constipation often experience impaired quality of life (QOL). A previous open-label study of Bifidobacterium bifidum G9-1 (BBG9-1) in patients with chronic constipation reported a significant improvement in defecation-related QOL. Thus, we conducted a multicenter, randomized controlled study to assess the efficacy of BBG9-1 in patients with chronic constipation.
methodsPatients diagnosed with or being treated for chronic constipation between July 2020 and January 2022 and having an overall score of ≥1 on the Japanese version of the patient assessment of constipation quality of life scale (JPAC-QOL) were included. Following a 2-week baseline period, BBG9-1 or placebo was administered for 8 consecutive weeks. The primary endpoint was the change in the JPAC-QOL overall score pre-administration and 8 weeks post-administration of BBG9-1; secondary endpoints were changes in JPAC-QOL subscale scores, number of days of defecation, stool consistency, straining during defecation, and feeling of incomplete evacuation after defecation pre-administration and 8 weeks post-administration.
resultsData from 140 patients (83 women) were analyzed. The JPAC-QOL overall score improved by 0.65 ± 0.56 in the treatment group and 0.54 ± 0.67 in the placebo group, with no significant difference (p = 0.282). However, the physical discomfort subscale showed a nominally significant improvement in the treatment group (p = 0.041). Stratified analysis revealed increased defecation frequency and reduced straining in those with high baseline straining scores. No adverse events were reported.
conclusionBBG9-1 administration reduced physical discomfort but did not significantly improve the JPAC-QOL overall score, indicating its limited effect on chronic constipation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.